

## **PYC THERAPEUTICS TO HOST Q2 INVESTOR CALL ON 31 MAY 2022 AT 9.00AM AWST | 11AM AEST**

**PERTH, Australia and SAN DIEGO, California – 27 May 2022** – PYC Therapeutics (ASX:PYC) is a biotechnology company combining two complementary platform technologies:

- RNA drug design capabilities; and
- a proprietary drug delivery technology.

Together they are being developed to create a new generation of RNA therapeutics to change the lives of patients with genetic diseases.

PYC CEO Dr. Rohan Hockings will host an investor call on 31 May 2022 at 9am AWST (11am AEST, 9pm US EST) to provide an update on:

- i) the Company's transition to a clinical-stage company;
- ii) PYC's co-lead retinitis pigmentosa type 11 program; and
- iii) PYC's pipeline of RNA therapies.

Investors can register for the call and submit questions for the Q&A session by emailing [info@pyctx.com](mailto:info@pyctx.com) and register for the call here:

<https://us02web.zoom.us/meeting/register/tZIocu2tpzwpEtSkjLxKjKKmXWXI5MI0Hjw6>

After registering, you will receive a confirmation email containing information about joining the meeting.

A link to the call will be available in the "Events" section on the "Investor & media center" page of the PYC website at <https://pyctx.com/investors-and-media/>.

### **About PYC Therapeutics**

PYC Therapeutics (ASX: PYC) is a pre-clinical stage biotechnology company pioneering a new generation of RNA therapeutics that utilise the Company's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC's PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today.

The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodegenerative and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are located in Australia and its translational, clinical,

regulatory and business development operations are located in the United States. For more information, visit [pyctx.com](http://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

### **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorized for release by the CEO of PYC Therapeutics Limited*

### **CONTACTS:**

**INVESTORS**  
info@pyctx.com

**MEDIA**  
Michelle Di Lello  
Michelle.DiLello@pyctx.com